Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)

Market Cap	3.68B -27.2%
Revenue (ttm)	892.24M +2.0%
Net Income	178.37M -44.1%
EPS	2.24 -44.4%
Shares Out	77.38M
PE Ratio	21.23
Forward PE	n/a
Dividend	2.00 (4.15%)
Ex-Dividend Date	n/a

Volume	519,874
Open	48.28
Previous Close	48.16
Day's Range	47.20 - 48.35
52-Week Range	47.21 - 78.20
Beta	0.25
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 31, 2026

About Hangzhou Alltest Biotech

Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; fluorescence immunoassay tests and analyzers; urine analysis solutions, biochemistry reagents, VTM, blood glucose monitoring systems, and HB hemoglobin te...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 2009
• Employees: 992
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 688606

Financial Performance

In 2025, Hangzhou Alltest Biotech's revenue was 905.34 million, an increase of 4.47% compared to the previous year's 866.58 million. Earnings were 220.19 million, a decrease of -27.20%.